Department of Endocrinology and Metabolic Diseases CCM

Projects

• Beobachtungsstudie GET - Growth Hormone Deficiency and Efficacy of Treatment
• BIM23A760 - Efficacy and safety of repeated subcutaneous administration of different doses in acromegalic patients.
• BPLG-005: Sustained release of human growth hormone in adult GHD
• CSOM230C2110
• CSOM230D2203 Basket-Studie
• Detection of GH-doping
• Efficacy of adjuvant Mitotane treatment in prolonging recurrence-free survival in pat.with adrenocortical carcinoma
• eF-ment-309643
• FIRM-ACT - First Internat. Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment
• GH-Doping: Development of a test method to detect GH abuse in sports
• Glukosetoleranz in der Akromegalie: Einfluss des Wachstumshormon-Exzesses auf Glukosestoffwechsel und Insulinresist
• Hormonal Regulation of Energy Metabolism, Body Weight and Growth. GRK 1208/1
• HypoCCS: The Global Hypopituitary Control and Complications Study
• International Cooperative Growth Study / International Cooperative Metabolic Study
• Lanreotide Autogel + Pegvisomant in Acromegaly
• Lysodren-Pharmakokinetik-Studie im Rahmen der FIRM-ACT-Studie
• Open-label, multi-center, expanded access study of pasireotide s.c. in pat. with Cushing's disease
• OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma
• Pasireotide LAR vs. Octreotide LAR in patients with active acromegaly
• Pegvisomant (MES03014/PEGA-0435-005; MES03013/PEGA-0435-003)
• PHOENIX-Studie
• SIRAC - Sunitnib in refractory adrenocortical carcinoma patients progressing after cytotoxic chemotherapy
• The mechanisms of isolated GH deficiency and construction of long acting GH agonists and antagonists

If the list does not contain any entry, the request was executed without results.